radioisotopes

R&D

Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.

News

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.